{"id":6644,"date":"2024-07-25T15:31:14","date_gmt":"2024-07-25T19:31:14","guid":{"rendered":"https:\/\/bridgebio.local\/?page_id=6644"},"modified":"2024-07-26T16:15:13","modified_gmt":"2024-07-26T20:15:13","slug":"u-s-expanded-access-policy","status":"publish","type":"page","link":"https:\/\/bridgebio.com\/us-expanded-access-policy\/","title":{"rendered":"U.S. Expanded Access Policy"},"content":{"rendered":"<p><span data-contrast=\"auto\">BridgeBio is on a mission to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases, and is dedicated to serving these individuals, their families, and the communities they are part of through education, empathy, and awareness.<\/span><\/p>\n<p><span data-contrast=\"auto\">Consistent with our mission to bring innovative medicines to patients with serious or life-threatening genetic conditions, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible. We are privileged to collaborate with clinical investigators and with patients who participate in our studies to develop new, safe and effective therapies. We believe this approach will serve patients who could be helped by the therapies we are developing. At the same time, we understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. In these circumstances, BridgeBio may consider providing a requesting physician with pre-approval access to a specific investigational drug being developed by BridgeBio, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met. These conditions, though not exhaustive, may include the following:<\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">The patient has a serious or life-threatening illness or condition and is either no longer responsive to or no longer able to tolerate any available treatment option;<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">The investigational drug is in active clinical development with sufficient data available to determine an appropriate dose and schedule for the patient\u2019s specific condition;\u00a0<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Making the investigational drug available will not negatively impact or delay the conduct of clinical trials or regulatory review or approval of the investigational drug for broader patient access; <\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">The requesting physician must have the Institutional Review Board (IRB) of the treating hospital or clinic review and approve the decision for the patient to use the medicine and comply with all regulatory obligations and BridgeBio requirements, including obtaining patient consent, patient monitoring, and safety reporting; <\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">A benefit-risk analysis, based on both the available clinical data as well as the requesting physician\u2019s assessment of the individual patient\u2019s condition and history, supports making the investigational drug available; and<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Adequate supply of the investigational drug is available.<\/span><\/li>\n<\/ul>\n<p>We continually evaluate the benefit-risk profile of each of our investigational drugs based on evolving clinical data. Each compound under development is different and the fact that one investigational drug is made available for the treatment of a particular patient does not mean it will be made available in response to other requests on behalf of other patients whose circumstances and medical histories may be different, or that a different investigational drug will be made available under our policy. Requests will be considered on a case-by-case basis.<span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">BridgeBio is committed to evaluating all requests in a fair and equitable manner. All requests must be submitted by the patient\u2019s treating physician; BridgeBio may require more detailed information to fully evaluate a request. Each request will be given careful consideration by BridgeBio whose decisions are final. Physicians seeking pre-approval access for patients with no alternative treatment options should submit their requests<\/span><span data-contrast=\"auto\"> to <\/span><a href=\"mailto:medinfo@bridgebiodev.wpengine.com\"><span data-contrast=\"none\"><strong>medinfo@bridgebiodev.wpengine.com<\/strong><\/span><\/a><span data-contrast=\"auto\">. BridgeBio will acknowledge receipt of requests within 5 days.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BridgeBio is on a mission to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases, and is dedicated to serving these individuals, their families, and the communities they are part of through education, empathy, and awareness. Consistent with our mission to bring innovative medicines to patients with serious or [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/page-plain.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-6644","page","type-page","status-publish","hentry"],"acf":{"hero_background_color":"red","hero_image":false,"hero_video":false,"hero_title":"U.S. Expanded Access Policy","hero_cta_type":"","hero_cta_text":"","hero_cta_internal_link":false,"hero_cta_external_link":"","hero_cta_video":false,"page_intro_text":"","page_content_primary":"","page_content_secondary":"","page_content_tertiary":"","hide_page_title":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>U.S. Expanded Access Policy - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/us-expanded-access-policy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Expanded Access Policy - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio is on a mission to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases, and is dedicated to serving these individuals, their families, and the communities they are part of through education, empathy, and awareness. Consistent with our mission to bring innovative medicines to patients with serious or [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/us-expanded-access-policy\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-26T20:15:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/us-expanded-access-policy\/\",\"url\":\"https:\/\/bridgebio.com\/us-expanded-access-policy\/\",\"name\":\"U.S. Expanded Access Policy - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2024-07-25T19:31:14+00:00\",\"dateModified\":\"2024-07-26T20:15:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/us-expanded-access-policy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/us-expanded-access-policy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/us-expanded-access-policy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Expanded Access Policy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. Expanded Access Policy - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/us-expanded-access-policy\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Expanded Access Policy - BridgeBio","og_description":"BridgeBio is on a mission to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases, and is dedicated to serving these individuals, their families, and the communities they are part of through education, empathy, and awareness. Consistent with our mission to bring innovative medicines to patients with serious or [&hellip;]","og_url":"https:\/\/bridgebio.com\/us-expanded-access-policy\/","og_site_name":"BridgeBio","article_modified_time":"2024-07-26T20:15:13+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BridgeBioPharma","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/us-expanded-access-policy\/","url":"https:\/\/bridgebio.com\/us-expanded-access-policy\/","name":"U.S. Expanded Access Policy - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2024-07-25T19:31:14+00:00","dateModified":"2024-07-26T20:15:13+00:00","breadcrumb":{"@id":"https:\/\/bridgebio.com\/us-expanded-access-policy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/us-expanded-access-policy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/us-expanded-access-policy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"U.S. Expanded Access Policy"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages\/6644"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=6644"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages\/6644\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=6644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}